Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography

Abstract

Distinct quantum metabolic values of -1 and 0 were noted in NHL. Aggressive NHL has a more negative value (or higher glucose sensitivity) than that of indolent and, thus, is more susceptible to extreme glucose variation.

Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck

“…Retrospective analyses have found that poor survival was associated with poor performance, an elevated level of lactate dehydrogenase (LDH), the presence of B symptoms, local tumor invasiveness, paranasal extension, regional lymph node involvement, and a high EBV DNA titer (6,7,(9)(10)(11). 18 F-FDG PET has been used increasingly to monitor treatment and follow-up in patients with lymphoma (12)(13)(14)(15)(16). Because the intensity of tumor 18 F-FDG uptake can distinguish between indolent and aggressive forms of lymphomas (17,18), 18 F-FDG PET can be used to identify the subset of patients who might respond to chemoradiation therapy.…”

“…18 F-FDG PET has been used increasingly to monitor treatment and follow-up in patients with lymphoma (12)(13)(14)(15)(16). Because the intensity of tumor 18 F-FDG uptake can distinguish between indolent and aggressive forms of lymphomas (17,18), 18 F-FDG PET can be used to identify the subset of patients who might respond to chemoradiation therapy. This may affect the prognostic stratification and clinical management of patients with lymphoma.…”

“…Patients were included if they had a pathologically confirmed diagnosis of ENKTL, according to the WHO classification; the NK/T-cell type as proven by immunohistochemical, flow cytometry, or EBV in situ hybridization analysis; and primary lesions within the nasal cavity, nasopharynx, or other head and neck regions and secondary spread to other organs. To be included, patients also had to have undergone wholebody 18 F-FDG PET before initial treatment. Patients with other types of NK or T-cell lymphomas or primary lesions outside the head and neck or those who were not assessed by pretreatment 18 F-FDG PET were excluded.…”

“…To be included, patients also had to have undergone wholebody 18 F-FDG PET before initial treatment. Patients with other types of NK or T-cell lymphomas or primary lesions outside the head and neck or those who were not assessed by pretreatment 18 F-FDG PET were excluded. All patients underwent pretreatment staging work-ups, including panendoscopy of the upper aerodigestive tract, chest radiography, CT/MRI of the head and neck, CT of the abdomen and pelvis, bone marrow examination, and whole-body 18 F-FDG PET.…”

“…Patients fasted for at least 6 h before 18 F-FDG PET, and their blood glucose concentrations were measured; patients with diabetes mellitus were required to have blood glucose concentrations of less than 11.0 mmol/L before the scan. All patients had rested for at least 1 h before the PET scan.…”